Midazolam: Dosing, Contraindications, and Monitoring

Midazolam is effective and safe for procedural sedation when titrated slowly (over at least 2 minutes with 2+ minute intervals between doses), with respiratory depression being the primary risk that requires continuous cardiorespiratory monitoring and immediate availability of resuscitation equipment.

Procedural Sedation Dosing

Adults

Healthy adults <60 years:

Start with ≤2.5 mg IV over 2 minutes 1
Wait 2+ minutes to evaluate effect (peak CNS effect takes 3-5 minutes) 1
Titrate in small increments to clinical effect (e.g., slurred speech)
Total dose rarely exceeds 5 mg 1
With opioid premedication: reduce dose by ~30% 1

Adults ≥60 years, debilitated, or chronically ill:

Start with ≤1.5 mg IV over 2 minutes 1
Wait 2+ minutes between doses
Maximum increment: 1 mg over 2 minutes 1
Total dose rarely exceeds 3.5 mg 1
With CNS depressant premedication: reduce dose by ≥50% 1
Critical pitfall: Peak effect takes longer in elderly—slower titration is mandatory to prevent oversedation

Intramuscular route:

0.07-0.08 mg/kg (approximately 5 mg) up to 1 hour before procedure 1
Elderly: 2-3 mg (0.02-0.05 mg/kg) may suffice 1

Pediatrics

The combination of fentanyl and midazolam is effective for procedural sedation (Level B recommendation) 2, though nondissociative agents should be titrated to clinical effect 2.

IV dosing (non-neonatal):

<6 months: 0.05-0.1 mg/kg initial dose; total up to 0.6 mg/kg (usually ≤6 mg); titrate in small increments over 2-3 minutes with 2-3 minute intervals 1
6 months-5 years: 0.05-0.1 mg/kg initial; total up to 0.6 mg/kg (usually ≤6 mg) 1
6-12 years: 0.025-0.05 mg/kg initial; total up to 0.4 mg/kg (usually ≤10 mg) 1
12-16 years: Dose as adults; total usually ≤10 mg 1
With opioids: Reduce both midazolam and opioid doses 1

IM dosing:

0.1-0.15 mg/kg for sedation/anxiolysis (usually effective, doesn't prolong emergence) 1
Up to 0.5 mg/kg for more anxious patients; total usually ≤10 mg 1

Intranasal dosing:

Optimal doses: 0.4-0.5 mg/kg for laceration repair 3
Lower doses (0.2-0.3 mg/kg) were eliminated in adaptive trial due to inadequate sedation 3
Critical caveat: 0.1 mg/kg intranasal is subtherapeutic—associated with 25% redosing rate versus 14% for alternate routes 4

Oral dosing:

0.25-1.5 mg/kg range reported; efficacy demonstrated from 0.25 mg/kg and above 5
Response rates: 36.7%-97.8% depending on dose and context 5
Higher doses increase risk of adverse events and oversedation 5

Key pediatric considerations:

Younger children (<6 years) require higher mg/kg doses than older children 1
Calculate dose based on ideal body weight in obese patients 1
Pediatric patients take ~3x longer than diazepam to reach peak EEG effect 1

Anesthesia Induction

Adults:

Unpremedicated: 0.3-0.35 mg/kg IV over 20-30 seconds 1
With narcotic premedication: 0.15-0.35 mg/kg (typically 0.25 mg/kg) 1
Elderly/debilitated: 0.15-0.3 mg/kg 1
Midazolam is less predictable than thiopental but safer in elderly and cardiovascular disease patients 6

Acute Seizure Control

Status epilepticus treatment:

Benzodiazepines (including midazolam) recommended as first-line for early SE 7
IM midazolam: 15 mg initial dose in adults, effective in 84% (30/36 cases with single dose) 8
Additional IM doses (15 mg q8h × 24h) if recurrence after initial control 8
Switch to IV if IM fails 8

Refractory SE:

Midazolam recommended by 12/12 guidelines for RSE 7
Continuous infusion in non-ICU settings: low-dose (<0.23 mg/kg/h) effective in 84.2% of pediatric cases 9
Titrate to burst-suppression or seizure suppression on EEG 7

Contraindications and Precautions

Absolute contraindications:

Acute narrow-angle glaucoma
Known hypersensitivity to benzodiazepines

High-risk populations requiring dose reduction:

COPD or decreased pulmonary reserve 1
Concomitant CNS depressants or opioids 1
Elderly (≥60 years) 1
Debilitated or chronically ill patients 1
Hepatic impairment 6
Neonates <6 months (particularly vulnerable to airway obstruction) 1

Avoid:

Intra-arterial injection 1
Extravasation 1

Monitoring Requirements

Mandatory continuous monitoring:

Respiratory function (pulse oximetry) 1
Cardiac function 1
Sedation level (e.g., Observer's Assessment of Alertness/Sedation scale) 1

Personnel and equipment:

Immediate availability of resuscitative drugs 1
Age- and size-appropriate airway equipment 1
Personnel trained in airway management 1
For deeply sedated pediatric patients: dedicated monitor separate from proceduralist 1

Sedation is a continuum—patients can easily progress from light to deep sedation with loss of protective reflexes, especially in children 1

Adverse Effects

Most concerning:

Respiratory depression (most common serious adverse effect) 2
Airway obstruction 1
Apnea 1
Hypotension 1

Common but less serious:

Drowsiness 8
Pain at injection site 2
Myoclonus (benign, not epileptogenic) 2

Paradoxical reactions:

Agitation, involuntary movements, hyperactivity, combativeness reported in adults and children 1
Exercise caution before continuing if these occur 1

Drug Interactions

Compatible in same syringe with:

Morphine sulfate 1
Meperidine 1
Atropine sulfate 1
Scopolamine 1

Dilution compatibility:

5% dextrose in water (24 hours) 1
0.9% sodium chloride (24 hours) 1
Lactated Ringer's (4 hours) 1

Clinical Pearls

Titration is paramount: Multiple small doses with adequate time intervals prevent oversedation 1
The 1 mg/mL formulation facilitates slower injection for procedural sedation 1
Midazolam is 2-4× more potent than diazepam 6
Onset: 15 minutes IM (peaks 30-60 minutes); 3-5 minutes IV 1, 6
Narcotic premedication reduces variability in response and decreases required midazolam dose 1
For bronchoscopy: narcotic premedication recommended; for peroral procedures: topical anesthetic recommended 1
Flumazenil should be available for reversal if needed

What are the appropriate dosing regimens, contraindications, and monitoring recommendations for midazolam in adult and pediatric procedural sedation, anesthesia induction, and acute seizure control?

Have a follow-up question?